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Regular Article
PLATELETS AND THROMBOPOIESIS

Cellubrevin/vesicle-associated membrane protein-3–mediated
endocytosis and trafﬁcking regulate platelet functions
Meenakshi Banerjee,1 Smita Joshi,1 Jinchao Zhang,1 Carole L. Moncman,1 Shilpi Yadav,2 Beth A. Bouchard,3 Brian Storrie,2
and Sidney W. Whiteheart1
1

Department of Molecular and Cellular Biochemistry, University of Kentucky, Lexington, KY; 2Department of Physiology and Biophysics, University of
Arkansas for Medical Sciences, Little Rock, AR; and 3Department of Biochemistry, University of Vermont, Burlington, VT

Endocytosis is key to fibrinogen (Fg) uptake, trafficking of integrins (aIIbb3, avb3), and
purinergic receptors (P2Y1, P2Y12), and thus normal platelet function. However, the
molecular machinery required and possible trafficking routes are still ill-defined. To
• Platelet VAMP-3 mediates
further identify elements of the platelet endocytic machinery, we examined the role of a
receptor-mediated
vesicle-residing, soluble N-ethylmaleimide factor attachment protein receptor (v-SNARE)
endocytosis and endocytic
called cellubrevin/vesicle-associated membrane protein-3 (VAMP-3) in platelet functrafficking of cargo.
tion. Although not required for normal platelet exocytosis or hemostasis, VAMP-32/2 mice
• Platelet VAMP-3 regulates
had less platelet-associated Fg, indicating a defect in Fg uptake/storage. Other granule markers
spreading, clot retraction,
were unaffected. Direct experiments, both in vitro and in vivo, showed that loss of VAMP-3 led
and TPOR/Janus kinase 2
to a robust defect in uptake/storage of Fg in platelets and cultured megakaryocytes. Uptake
signaling.
of the fluid-phase marker, dextran, was only modestly affected. Time-dependent uptake
and endocytic trafficking of Fg and dextran were followed using 3-dimensional–structured
illumination microscopy. Dextran uptake was rapid compared with Fg, but both cargoes progressed through Rab41, Rab111, and von
Willebrand factor (VWF)1 compartments in wild-type platelets in a time-dependent manner. In VAMP-32/2 platelets, the 2 cargoes showed
limited colocalization with Rab4, Rab11, or VWF. Loss of VAMP-3 also affected some acute platelet functions, causing enhanced spreading on
Fg and fibronectin and faster clot retraction compared with wild-type. In addition, the rate of Janus kinase 2 phosphorylation, initiated through
the thrombopoietin receptor (TPOR/Mpl) activation, was affected in VAMP-32/2 platelets. Collectively, our studies show that platelets are
capable of a range of endocytosis steps, with VAMP-3 being pivotal in these processes. (Blood. 2017;130(26):2872-2883)

Key Points

Introduction
Blood platelets respond to vascular damage via activation, adhesion,
spreading, and subsequent granule exocytosis.1 Endocytosis, in contrast, is important for cargo packaging (eg, ﬁbrinogen [Fg]) into granules.2-4
However, platelet endocytosis could also be critical for actively sensing
changes in vascular microenvironments and responding to what is being
taken up. This is a more dynamic view of platelets as active surveyors of
the vasculature, extending the importance of platelet endocytosis
beyond granule biogenesis, and perhaps even beyond hemostasis. The
mechanistic underpinnings of endocytosis and its importance in platelets
are, however, understudied, in part because of a lack of experimental
tools.5 In this manuscript, we report the characterization of a mouse
strain whose platelets are defective in endocytic trafﬁcking of cargo.
Endocytosis refers to cargo uptake and receptor trafﬁcking to
and from the plasma membrane through distinct membrane-bound
compartments called endosomes. Seminal studies from the 1980s
provided the ﬁrst glimpses into the presence of active endomembrane systems in platelets. Platelets have clathrin-coated vesicles6,7
and can endocytose several plasma proteins (eg, albumin, immunoglobulin G, Fg, von Willebrand factor [VWF], ﬁbronectin)

and translocate them to a-granules.3,8-11 Notably, both clathrindependent and clathrin-independent endocytosis have been reported
in platelets.12 In addition, several platelet surface receptors such as
integrin aIIbb3 and glycoprotein Ib are internalized and then
recycled back to the plasma membrane.13-16 Platelet CLEC-2 is
internalized in a Syk-independent manner, whereas Arrestin-2 and
Arf6 play crucial roles in endocytic trafﬁcking of the P2Y 12
receptors.17,18 ADP and thrombin stimulation leads to translocation
of internal pools of receptors and their surface redistribution.15,19-21
Consistent with these reports of platelet endocytosis, platelets
contain key endocytic proteins and regulators, including the
vesicle-scission-inducing GTPase, dynamin, dynamin-related protein 1, and adaptor proteins such as disabled-2.22-27 Recently, we
highlighted the role of adenosine 59-diphosphate (ADP)-ribosylation
factor 6 (Arf6), a small GTP-binding protein, that speciﬁcally regulates aIIbb3-mediated Fg uptake/storage, and hence modulates acute
platelet functions such as clot retraction and spreading.28 These studies
are further supported by “omics” analyses,29,30 which highlight the
burgeoning importance and complexity of endocytosis in platelets.
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Figure 1. VAMP-32/2 platelets had lower fibrinogen
levels. (A) Fg levels in washed platelet extracts from WT
and VAMP-32/2 mice (3 each) were measured by western
blotting. b-actin was used as loading control. (B) Quantification of Fg levels in panel A was performed using
ImageQuantTL and plotted with SigmaPLot software
(v13.0). (C) Comparison of protein levels by western
blotting between WT and VAMP-32/2 platelets. Washed
platelet extracts (5 3 107 platelets/lane) were loaded, and
the indicated proteins were probed by western blotting. (D)
Quantification of protein levels was performed using
ImageQuantTL, and data were plotted as the ratio of
VAMP-32/2 over WT. The dashed line represents the ratio
1 of KO/WT protein levels. Statistical analyses were done
using Student t test; ***P # .001. Data for panels C and D
are representative of platelets pooled from 2 to 3 mice in at
least 2 independent experiments.
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Here we describe a role for cellubrevin/vesicle-associated membrane protein-3 (VAMP-3) in mediating endocytosis and endosomal
trafﬁcking in platelets. This v-SNARE has been reported to be localized
to intracellular punctate structures within platelets.31 Using a knockout
(KO) mouse, with normal hemostasis and whose platelets had no aggregation or secretion defects,32 we demonstrated that VAMP-3 plays
a role in Fg uptake and governs platelet endocytosis. VAMP-3 deletion
caused defective aIIbb3-mediated Fg uptake and accumulation, whereas
ﬂuid phase pinocytosis, as monitored by dextran uptake, was only
marginally affected, both in vivo and ex vivo. Platelet spreading on Fg and
thrombin-stimulated clot retraction was faster in the VAMP-32/2 platelets.
In addition, we demonstrated that platelets sort endocytosed cargo into
discrete endosomal compartments in vivo and ex vivo, and this process
was defective in VAMP-32/2 platelets. Collectively, our work presents
VAMP-3 as a regulator of platelet endocytosis, and this knockout animal
model adds to the repertoire of tools for studying endocytic trafﬁcking
in platelets while maintaining normal exocytosis and hemostasis.

Methods
See supplemental Methods (available on the Blood Web site) for additional
materials and methods.

Plate assay to measure endocytosis
Opaque/black 96-well polystyrene plates (Corning, Corning, NY) were coated
with 5% bovine serum albumin in phosphate-buffered saline (PBS) overnight at
room temperature (RT). Wild-type (WT) and KO washed platelets (100 mL;
5 3 107/mL), preincubated with 1 mM CaCl2 for 5 minutes, were added to each
well and incubated with varying concentrations of ﬂuorescein isothiocyanate
(FITC)–Fg (Invitrogen, Carlsbad, CA), low-molecular-weight (10 kDa) Oregon
Green 488-Dextran (Invitrogen), or Alexa 568-Transferrin (Invitrogen) for
increasing times at 37°C. Fluorescence intensities were measured using a
SpectraMax plate reader (Molecular Devices, Sunnyvale, CA) before and after
addition of 0.04% trypan blue (TB; 0.04% TB quenched .95% of FITC signal,
Oregon Green 488 signal, and Alexa 568 signal, data not shown) to stop
reactions at various times. Standard curves were generated using serial dilutions
of FITC-Fg or Oregon Green 488-Dextran or Alexa 568-Transferrin.
Three-dimensional–structured (3D) illumination superresolution microscopy
Washed WT and KO platelets (1.0 3 109/mL) were incubated ex vivo with
Alexa 647-Fg and Oregon Green 488-Dextran (1 mM each) at 37°C for
indicated times and then ﬁxed with 2% paraformaldehyde (PFA). Centrifugation (700g for 5 minutes) was used to remove ﬁxative, and platelet pellets were
resuspended in PBS. The platelets were ﬁxed a second time with 2% PFA and
then allowed to settle onto poly-D-lysine-coated coverslips (0.1 mg/mL) for
more than 90 minutes at RT in a humid chamber. To quench the ﬁxative,
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coverslips were incubated cell side down in 50 mM NH4Cl in PBS for
30 minutes at RT. Coverslips were washed with 13 PBS and mounted in
Prolong Diamond Antifade Mounting medium (Invitrogen) and cured for
2 days at RT in the dark.
For in vivo experiments, 24 hours after injection of Alexa 647-Fg and
Oregon Green 488-Dextran (2 mM/mouse for both ﬂuorophores), mice were
euthanized and platelets were directly ﬁxed during the blood draw. Platelets
were then isolated and allowed to settle onto poly-D-lysine-coated coverslips.
Imaging was performed using the Ti-E N-STORM/N-SIM super-resolution
microscope (Nikon, Melville, NY), ﬁtted with an Apo SR 1003/1.49 NA oilobjective and A1R camera at the University of Kentucky Imaging Core. Images
were processed using NIS-Elements v3.2 N-SIM/STORM software (Nikon)
and Adobe Photoshop CS5 (Adobe, San Jose, CA).
Immunofluorescence microscopy
Washed WT and KO platelets (1.0 3 109/mL) were incubated ex vivo with Alexa
647-Fg and Oregon Green 488-Dextran (1 mM each) at 37°C and then ﬁxed with
2% PFA. Centrifugation (700g for 5 minutes) was used to remove ﬁxative, and
platelet pellets were resuspended in PBS. The platelets were then allowed to settle
onto poly-D-lysine-coated coverslips (0.1 mg/mL) and incubated overnight at
4°C. Platelets were then washed once with 13 PBS, reduced with 0.1% NaBH4
for 10 minutes at RT, rewashed with 13 PBS thrice for 15 minutes each with
gentle shaking, and then permeabilized for 15 minutes with 0.2% Triton X-100 in
13 PBS at RT. Cells were then blocked in 10% fetal bovine serum/0.05% Triton
X-100 in 13 PBS for 90 minutes at RT, followed by incubation with primary
antibodies prepared in 5% fetal bovine serum/0.05% Triton X-100 in 13 PBS
overnight at 4°C. The platelets were then washed 5 times with 13 PBS for
15 minutes each and incubated with secondary antibodies in 5% fetal bovine
serum/0.05% Triton X-100 in 13PBS for 1 hour at RT. Cells were washed 5 times
for 15 minutes each with 13 PBS and then postﬁxed with 4% PFA for 10 min.
After washing in 13 PBS once, coverslips were washed and mounted in Prolong
Diamond Antifade Mounting medium and cured for 2 days at RT in the dark.
Imaging was performed using the Nikon Ti-E N-STORM/N-SIM superresolution microscope, ﬁtted with an Apo SR 100X/1.49 NA oil objective and
A1R camera at the University of Kentucky Imaging Core. Images were processed
using NIS-Elements v3.2 N-SIM/STORM software (Nikon) and Adobe Photoshop CS5 (Adobe). Control experiments with only secondary antibodies (but no
primary antibodies) were performed to eliminate nonspeciﬁc staining artifacts
from immunoglobulin G binding.

Results
VAMP-32/2 platelets were Fg-deficient

Given past reports of Fg endocytosis by platelets3,10 and the intracellular localization of VAMP-3,31 we asked whether VAMP-3 played
a role in Fg uptake and/or accumulation. In Figure 1A-B, VAMP-32/2
platelets, isolated from 3 individual mice, had less platelet-associated
Fg (;40% less; P # .001) than WT littermates, indicating a defect
in uptake and/or accumulation of Fg. However, plasma Fg levels
were unchanged, suggesting loss of VAMP-3 did not affect Fg
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production (supplemental Figure 1). The major Fg-binding integrin,10
aIIbb3, was also unaffected by loss of VAMP-3 because b3 levels
were unchanged in the VAMP-32/2 platelets, as measured by western
blotting (Figure 1C-D). Ligands for other platelet integrins, for example, ﬁbronectin (binds to a5b1 and avb3) and vitronectin (binds to
avb3), were either unchanged or slightly elevated in VAMP-32/2
platelets (Figure 1C-D). Of note, vitronectin levels were also increased in the Arf62/2 platelets compared with WT.28 Levels of other
endocytic cargoes, such as VEGF and Sema3F (binds to VEGFR),
were unchanged. VAMP-3 is thought to localize on both Early and
Recycling endosomes.33,34 Markers for those compartments, Rab4
(Early), Rab11 (Recycling), and Rab7 (Late endosomes), were unchanged in VAMP-32/2 platelets (Figure 1C-D). Other platelet
endocytic markers, for example, dynamin-2, clathrin heavy chain,
and disabled-2, were also unchanged (Figure 1C-D). Levels of de novo
synthesized cargo, for example, platelet factor 4, and other platelet
SNARE proteins were unaltered in the VAMP-32/2 platelets.32 Defective Fg endocytosis did not alter the gross morphology of VAMP-32/2
platelets. Moreover, the VAMP-32/2 mice had normal platelet, red blood
cell, and white blood cell counts (supplemental Table 1), although their
platelet size was ;5% smaller than the platelets from age-matched
littermate controls. Thus, the reduced intraplatelet Fg observed in
VAMP-32/2 platelets was not a result of alterations in any of the
endocytic proteins and regulators analyzed, or decreased levels of
b3 integrins or plasma Fg.
Reduced levels of internalized Fg could be caused by decreased
surface and/or activated aIIbb3 levels. Surface levels of aIIbb3, under
resting conditions, were unchanged in the VAMP-32/2 platelets, as
measured by ﬂow cytometry (supplemental Figure 2Ai-iii). As expected,28 thrombin-induced activation mobilized an internal pool of
aIIbb3 integrins, as indicated by the ;25% increase in the total
surface aIIbb3. This ;25% increase was equally noted in both WT and
VAMP-32/2 platelets. Similarly (supplemental Figure 2Bi-iii), levels of
activated aIIbb3, as measured by Jon/A binding, were unchanged in
VAMP-32/2 platelets, consistent with normal aggregation.32 Defective
Fg uptake, despite normal levels of aIIbb3, could be attributed to
defective surface-binding of Fg to aIIbb3. Under steady-state conditions,
FITC-Fg binding at 2 different concentrations (0.06 and 0.12 mg/mL)
was unaffected in the VAMP-32/2 platelets (supplemental Figure 2C).
Taken together, these results indicated that the lower Fg levels in
VAMP-32/2 platelets were not a result of defective binding or
reduced surface levels of aIIbb3, suggesting VAMP-3 plays an
essential role in uptake and/or accumulation of Fg in platelets.
Fg uptake/storage was defective in VAMP-32/2 platelets

ADP stimulation enhances internalization of Fg-bound aIIbb3 into
platelets.20,21 We veriﬁed this observation using ﬂow cytometry to
measure FITC-Fg uptake in resting and ADP-stimulated WT and
VAMP-32/2 platelets (Figure 2A-B). Similar to Huang et al,28 we used

Figure 2. VAMP-32/2 platelets had defective fibrinogen uptake. WT and VAMP-32/2 platelets (1.0 3 109/mL) were kept resting (A) or stimulated with ADP (10mM) (B), then
incubated with FITC-Fg (0.06 or 0.12 mg/mL) at 37°C for 30 minutes. The platelets were then put on ice for 20 minutes and fixed with 2% PFA (final concentration), and geometric mean
fluorescent intensity measurements were taken by flow cytometry before and after the addition of 0.04% TB. Quantification of data shows both geometric mean fluorescence intensity
measurements before addition of TB (WT/ VAMP-32/2–TB; dark bars), which gives the total fluorescence, and after addition of TB (WT/ VAMP-32/21 TB; light bars), which gives the
measure of internal fluorescence. As explained in Methods, WT and VAMP-32/2 platelets were added to each well in an opaque 96-well plate and either incubated with FITC-Fg (2 mM) (C)
or low-molecular-weight (10 kDa) Oregon Green 488-Dextran (2 mM) (D) for times from 0 to 60 minutes at 37°C. Similarly, WT and VAMP-32/2 platelets were incubated with either FITC-Fg
(0.1-5 mM) (E) or low-molecular-weight (10 kDa) Oregon Green 488-Dextran (1-100 mM) (F) for 30 minutes at 37°C. Reactions were stopped at given points, and fluorescence was
measured before and after the addition of 0.04% TB. Data were plotted using SigmaPlot software (v13.0) and graphed as numbers of molecules of Fg or dextran endocytosed per platelet.
No ADP was added to the plate assays. Statistical analyses were performed using 1-way ANOVA test; *P # 0.05; **P # 0.01; ***P # .001; n.s., not significant. (G) Washed WT and
VAMP-32/2 platelets (1 3 109/mL) were incubated with FITC-Fg at final concentrations of 1 mM at 37°C for increasing times up to 30 minutes. Platelets were fixed with 2% PFA (final
concentration) and mixed with 0.1% TB before imaging. Platelets were visualized as described in the supplemental Methods. Exposure times for DIC were 100 ms, whereas for the FITC,
laser were 500 ms. Scale bars, 5 mM. (H) Quantification of the number of FITC1 puncta/platelet in both WT and VAMP-32/2 samples were plotted using SigmaPlot software (v13.0).
Statistical significance determined using Mann-Whitney U test; **P # .01. Data are representative of 3 independent experiments (mean 6 standard error of the mean [SEM]) for all.
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0.04% TB to quench external FITC ﬂuorescence (including the
ﬂuorescence that is trapped within the open canalicular system) and
measured TB-resistant ﬂuorescence as a metric of endocytosis. Platelets
were incubated with FITC-Fg, either in the presence or absence of
ADP, at 37°C, and then chilled on ice to arrest further endocytosis, ﬁxed
with 2% PFA, and analyzed using ﬂow cytometry before (darker bars)
and after (lighter bars) addition of TB. In the absence of TB, geometric
mean ﬂuorescence intensity measurements represent the total ﬂuorescence intensity of FITC-Fg present both inside and on the platelet
surface. In Figure 2A, under resting conditions, the total ﬂuorescence
intensity before the addition of TB was equivalent between WT and
VAMP-32/2 platelets, conﬁrming equal amounts of FITC-Fg bound in
each sample. Post-TB quenching, VAMP-32/2 platelets had ;50% less
FITC-Fg signal (P # .03 at 0.06 mg/mL and P # .006 at 0.12 mg/mL),
indicating that under steady-state conditions, VAMP-3 loss affected
internal accumulation of Fg in platelets. In Figure 2B, ADP stimulation
(10 mM) increased overall net ﬂuorescence for both WT and VAMP-32/2
platelets by ;30-fold, indicative of aIIbb3 activation caused by
ADP receptor signaling.20,21 Although VAMP-32/2 platelets had
enhanced Fg association comparable to WT, the internalized FITC-Fg
pool (resistant to TB) was still less, consistent with a ;50% deﬁcit
in internalized FITC-Fg (P # .039 at 0.06 mg/mL and P # .023 at
0.12 mg/mL). Collectively, these data suggest VAMP-3 deletion
leads to impaired endocytic uptake and/or accumulation of Fg into
platelets in both resting and activated states.
Endocytosis defects in VAMP-32/2 platelets: receptor-mediated
vs fluid-phase cargo

Platelets can internalize diverse cargoes; for example, vascular endothelial growth factor,35 bacteria, viruses,36 and so on. We asked whether
VAMP-3 could be a central mediator of cargo uptake in platelets. Uptake of ﬂuorescently tagged receptor-mediated cargo (Fg) and ﬂuidphase pinocytosis cargo (low-molecular-weight dextran) was tracked in
a plate-based assay using TB as a quencher of external ﬂuorescence. In
Figure 2C,E, WT platelets internalized FITC-Fg in a time-dependent (up
to 60 minutes) and dose-dependent (up to 5 mM) manner. VAMP-32/2
platelets showed a robust defect in both time- and dose-dependent
Fg uptake. Arf62/2 platelets were also defective in FITC-Fg uptake
(supplemental Figure 3A,C), conﬁrming our earlier studies.28 On the
basis of these data, Fg internalization within WT platelets exhibited
time- and dose-dependence that appeared to saturate. This is indicative
of a receptor-mediated endocytosis process.
Fluid-phase endocytosis/pinocytosis was constitutive in WT platelets
and showed a linear increase in dextran uptake with time (Figure 2D) and
concentration (Figure 2F). Loss of VAMP-3 modestly affected dextran
uptake, but there was still a time- and dose-dependence, similar to WT.
Loss of Arf6 appeared to have a greater effect on ﬂuid-phase uptake
(supplemental Figure 3B,D). Our data agreed with reports of normal
small-molecule pinocytosis, for example, horseradish peroxidase, in
VAMP-32/2 mouse embryonic ﬁbroblasts.37,38 Interestingly, from a
quantitative perspective, more dextran molecules were endocytosed than
Fg (1018 vs 1015 molecules/platelet over the course of 60 minutes). These
data were consistent with ﬂuid-phase pinocytosis having a higher overall
capacity than receptor-mediated uptake. Collectively, our data suggested
that both VAMP-3 and Arf6 are more important for receptor-mediated
uptake of Fg in platelets than for ﬂuid-phase pinocytosis.
Low-resolution epiﬂuorescence microscopy conﬁrmed these results.
WT and VAMP-32/2 platelets were incubated with 1 mM FITC-Fg for
30 minutes, ﬁxed, treated with 0.04% TB to quench external ﬂuorescence,
and imaged by epiﬂuorescence. WT platelets had more FITC-Fg1 puncta
than VAMP-32/2 platelets after 30 minutes (Figure 2G). Quantiﬁcation
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of total ﬂuorescent puncta present per platelet showed that more than
80% of VAMP-32/2 platelets (vs ;30% in WT) had no puncta,
consistent with defective Fg uptake (Figure 2H; overall P # .01). Only
WT platelets had 3 or more puncta compared with 2 or fewer in VAMP32/2 platelets. Cultured VAMP-32/2 megakaryocytes, when incubated
with Alexa 647-Fg (1 mM), also showed fewer Fg1 puncta (60% fewer
in VAMP-32/2 at 60 minutes; supplemental Figure 4) compared with
WT, suggesting defective Fg uptake/storage in megakaryocytes as well
as in platelets. Collectively, our data suggest VAMP-3 is important for
ﬁbrinogen uptake in both megakaryocytes and platelets. Consistent with
our ex vivo plate-based assay that shows time-dependent uptake of
dextran (Figure 2D), quantiﬁcation of dextran1 ﬂuorescent puncta
(indicative of dextran uptake) in WT and VAMP-32/2 platelets at
30 minutes showed no signiﬁcant differences (supplemental Figure 5A-B).
Taken together, these data show that Fg uptake and/or accumulation
is dramatically reduced in the VAMP-32/2 platelets and comparatively
more affected than dextran uptake and/or accumulation. Because
aIIbb3 activation and Fg-binding to aIIbb3 remained unaffected
(supplemental Figure 2), it appears that VAMP-3 could be mediating
membrane trafﬁcking steps that are downstream of Fg binding and/or
internalization, yet required for Fg accumulation.
Sorting of endocytic cargo in platelets

To probe another receptor-mediated process, we examined the uptake
of Alexa 568-transferrin (supplemental Figure 6). Uptake was doseand time-dependent, as well as saturable, much like that seen with Fg
(Figure 2C,E). VAMP-32/2 platelets showed an obvious defect, consistent with VAMP-3 (and perhaps Arf6) being more important for
receptor-mediated uptake/storage of cargo than for ﬂuid-phase pinocytosis. This is also consistent with different endocytic trafﬁcking
routes being active in platelets. To address this point, platelets were coincubated with equimolar concentrations of Alexa 647-Fg and Oregon
Green 488-Dextran and imaged by 3D-structured illumination microscopy over time. At 1 minute, Fg (magenta, Figure 3A) was found at
the platelet plasma membrane (possibly bound to aIIbb3), whereas
dextran (green) already was internalized into punctate structures. Surface
staining for dextran was minimal, most likely because no speciﬁc dextran
receptor is present on platelets. At 5 minutes, while surface staining was
still visible, Fg1 puncta appeared, with a concomitant increase in
dextran1 puncta. By 30 minutes, more Fg-positive puncta appeared and
the surface localization was less apparent. Strikingly, Fg and dextran
puncta did partially overlap (indicated by the white spots as in Figure 3A,
C), suggesting the 2 cargoes might take different routes to a similar
compartment. Consistently, VAMP-32/2 platelets had fewer Fg puncta
compared with WT, whereas dextran uptake was less affected.
The accumulation of Fg and dextran in platelets was also examined
in vivo. Equimolar amounts of Alexa 647-Fg and Oregon Green
488-Dextran were injected via the retro-orbital sinus of VAMP-32/2
mice and WT littermate controls, and platelets were harvested and
imaged 24 hours postinjection. In both WT and VAMP-32/2 platelets,
Fg and dextran were localized to distinct compartments at 24 hours
(Figure 3B). VAMP-32/2 platelets had a robust defect in Fg accumulation
with very few ﬂuorescent puncta visible. Surprisingly, dextran1 puncta
were also diminished in VAMP-32/2 platelets, suggesting that loss
of VAMP-3 has a greater effect on accumulation during the longer
incubation times (24 hours) than during acute uptake at shorter times.
This argues that VAMP-3 is essential for both acute uptake and longterm accumulation/storage of receptor-mediated cargo (Fg), whereas it
preferentially affects accumulation/storage over acute uptake of ﬂuidphase pinocytic cargo. The integrity of the ﬂuorescently tagged dextran
was not evaluated, so its degradation could also explain our ﬁndings.
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Figure 3. Receptor-mediated and fluid-phase cargoes
took different endocytic routes in platelets. (A) Washed
WT and VAMP-32/2 platelets (1.0 3 109/mL) were incubated ex vivo with Alexa 647-Fg and Oregon Green
488-Dextran at final concentrations of 1 mM each and
incubated at 37°C for 1 to 30 minutes and prepared for 3Dstructured illumination microscopy imaging as described in
Methods. (B) WT and VAMP-32/2 mice were injected with
Alexa 647-Fg and Oregon Green 488-Dextran at a concentration of 2 mM each per fluorophore through the retroorbital
sinus. Twenty-four hours postinjection, platelets were
harvested and prepared for 3D-structured illumination
microscopy imaging. Slides from panels A and B were then
imaged using the Nikon Ti-E N-STORM/N-SIM superresolution microscope, and images were processed using
the NIS-Elements v3.2 N-SIM/STORM suite software. Scale
bars, 5 mm. Data are representative of at least 2 independent experiments. (C) Pearson’s correlation coefficients were calculated using the NIS-Elements v3.2 N-SIM/
STORM suite software to show overlap between Alexa 647Fg and Oregon Green 488-Dextran (depicted in white) at the
indicated points. Graph shows the mean 6 SEM of 2
independent experiments, with at least 30 cells per field,
taken over 3 to 4 fields per time. Statistical analyses were
performed using Student t test; n.s., not significant.
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To dissect the sorting routes present in platelets, we compared the
distribution of endocytosed Fg and dextran to that of Rab4 and Rab11,
markers for Early and Recycling endosomes, respectively (Figure 4). In
WT platelets, both cargoes were colocalized at 30 minutes and stayed so
at 60 minutes (Figures 3A and 4A-B, Ci). At 30 minutes, more of the Fg
and dextran colocalized with Rab4, suggesting an Early endosome
distribution (Figure 4A,Cii-iii). By 60 minutes, more of the Fg and
dextran colocalized with Rab11 (and less so with Rab4), suggesting
a Recycling endosome distribution (Figure 4B-Civ-v). The timedependent transit between compartments is consistent with previous
studies.28 To examine cargo trafﬁcking in VAMP-32/2 platelets, we
focused on the few that were Fg1. The endocytosed cargo had a distinctly different distribution. As expected, Fg levels were lower than
seen in WT, and fewer platelets were positive for Fg. The little that was
taken up partially colocalized with endocytosed dextran (Figure 4).

5 min

30 min

24 hr

The overlap between Fg and Rab4 or Rab11 was less obvious at
both 30 and 60 minutes. This was also true for endocytosed dextran,
suggesting loss of VAMP-3 affected the interendosomal trafﬁcking
seen in WT platelets. However, based on these altered distributions of
cargoes, it is unclear which step or steps VAMP-3 mediates. In WT
platelets, some of the endocytosed Fg and dextran colocalized with
VWF (a marker for a-granules) as early as 30 minutes (Figure 5A-B),
consistent with previous studies.39 There was poorer colocalization
of endocytosed Fg and dextran with VWF in VAMP-32/2 platelets,
again suggesting VAMP-3 is needed for correct intercompartmental
transit in platelets.
Loss of VAMP-3 affected TPOR/Mpl receptor signaling

Because VAMP-3 mediates trafﬁcking of several transmembrane
receptors, such as the transferrin receptor (supplemental Figure 6; Galli
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Figure 4. Loss of VAMP-3 affected transit of cargoes to endosomes. Washed platelets (1 3 109/mL) were incubated with Alexa 647-Fg and Oregon Green 488-Dextran at
final concentrations of 1 mM each and incubated at 37°C for 30 to 60 minutes and prepared for immunofluorescence microscopy, as described in Methods. Platelets were
incubated with anti-Rab4 rabbit polyclonal antibody (1:250 dilution) and anti-Rab11 rabbit polyclonal antibody (1:250 dilution), and then with Alexa 568-conjugated goat antirabbit IgG secondary antibody (1:1,000 dilution). Images were taken using the Nikon Ti-E N-STORM/N-SIM super-resolution microscope and digitally magnified by 330. The
Alexa 647-Fg signal was faux-colored blue to aid in identifying overlaps. Scale bars, 1 mm. Data are representative of 2 independent experiments. (C) Pearson’s correlation
coefficients were calculated using the NIS-Elements v3.2 N-SIM/STORM suite software to show overlap among (i) Alexa 647-Fg and Oregon Green 488-Dextran (depicted in
cyan), (ii) Alexa 568-Rab4 and Alexa 647-Fg (depicted in magenta), (iii) Alexa 568-Rab4 and Oregon Green 488-Dextran (depicted in yellow), (iv) Alexa 568-Rab11 and Alexa
647-Fg (depicted in magenta), and (v) Alexa 568-Rab11 and Oregon Green 488-Dextran (depicted in yellow), at the indicated times. Overlap of all 3 fluorophores is depicted in
white in the merge panel. Graph shows the mean 6 SEM of 2 independent experiments, with at least 30 cells per field, taken over 3 to 4 fields per time. Statistical analyses
were performed using Student t test; *P # .05; **P # .01; ***P # .001; n.s., not significant.

et al40), we asked whether other receptors rely on VAMP-3dependent trafﬁcking. Thrombopoietin (TPO) binding to TPO
receptor (TPOR/Mpl) induces internalization of the receptor via
a dynamin-2 and clathrin-mediated process that initiates Janus
kinase 2 (JAK2) phosphorylation in platelets.22,41 In contrast to
dynamin-22/2 , VAMP-32/2 platelets did not exhibit constitutive

JAK2 phosphorylation. Instead, they showed a time-dependent
increase in phospho-JAK2 similar to WT. However, at each time,
phospho-JAK2 was markedly elevated in VAMP-32/2 (supplemental Figure 7A-B), with statistically signiﬁcant differences
at 15 minutes (P # .05) and at 30 minutes (P # .05). The levels
of total JAK2 were lower in the VAMP-32/2 platelets compared
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Figure 5. Loss of VAMP-3 affected transit of cargoes to a-granules. (A) Washed platelets (1 3 109/mL) were incubated with Alexa 647-Fg and Oregon green 488Dextran at final concentrations of 1 mM each and incubated at 37°C for 30 to 60 minutes and prepared for immunofluorescence microscopy, as described in Methods.
Platelets were incubated with anti-VWF rabbit polyclonal antibody (1:500 dilution) and then with Alexa 568-conjugated goat anti-rabbit immunoglobulin G secondary
antibody (1:1,000 dilution). Images were taken using the Nikon Ti-E N-STORM/N-SIM super-resolution microscope, and digitally magnified by 330. The Alexa 647-Fg
signal was faux colored blue to aid in identifying overlaps. Scale bar, 1 mm. Data are representative of 2 independent experiments. (B) Pearson’s correlation
coefficients were calculated using the NIS-Elements v3.2 N-SIM/STORM suite software to show overlap between (i) Alexa 568-VWF and Alexa 647-Fg (depicted in
magenta) and (ii) Alexa 568-VWF and Oregon Green 488-Dextran (depicted in yellow) at the indicated times. Overlap of all 3 fluorophores is depicted in white in the
merge panel. Graph shows the mean 6 SEM of 2 independent experiments, with at least 30 cells per field, taken over 3 to 4 fields per time. Statistical analyses were
performed using Student t test; *P # .05; **P # .01; ***P # .001; n.s., not significant.

with WT, but total TPOR was unchanged (supplemental Figure 7A).
Our data suggest that although TPOR levels may be unaffected, there
exists a VAMP-3-mediated membrane trafﬁcking step or steps that
occurs on TPO-bound TPOR internalization and that alters JAK2
phosphorylation. We also asked whether Arf6 could play a role in
signaling through the TPOR-JAK2 axis. Arf62/2 platelets demonstrated normal JAK2 phosphorylation on TPO induction similar to WT
platelets, with no change in TPOR levels (supplemental Figure 7C-D).
Arf6, thus, may be less important than VAMP-3 or dynamin-2 in
regulating TPOR/Mpl-JAK2 signaling. It should be noted that loss of
VAMP-3 did not affect total Arf6 levels or the rate of stimulationdependent Arf6-GTP to Arf6-GDP transition reported by Choi et al.42
However, there was a signiﬁcant increase in basal Arf6-GTP in
VAMP-32/2 platelets over time (supplemental Figure 8). The
significance of this is unclear at present.

Loss of VAMP-3 enhanced platelet spreading and clot retraction

VAMP-3 has been shown to modulate b1 integrin-dependent cell
adhesion and migration in epithelial cell lines.43,44 We asked whether
VAMP-3 plays a similar role in aIIbb3-mediated platelet spreading.
Consistent with unaltered steady-state binding to Fg (supplemental
Figure 2C), there were no statistically signiﬁcant differences in static
adhesion to Fg by VAMP-32/2 platelets (Figure 6C). To determine
whether VAMP-3 loss affected platelet spreading, we monitored WT
and VAMP-32/2 platelet spreading on Fg-coated surfaces over time at
37°C. VAMP-3 deletion caused faster spreading with signiﬁcantly
larger platelet surface areas covered in as early as 30 minutes (P # .05;
Figure 6A-B). The rate of spreading was 82% faster in the VAMP-32/2
platelets (rate of 0.80 mm2/min for VAMP-32/2 vs 0.44 mm2/min for
WT, assuming spreading is linear over time). In similar experiments,
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Figure 6. VAMP-32/2 platelets spread faster on Fg and had enhanced clot retraction. (A) Representative images of WT and VAMP-32/2 platelets allowed to spread on
fibrinogen (50 mg/mL in 13 PBS) for 60 minutes are shown. Images of spread platelets were taken using DIC microscopy as described in supplemental Methods. Exposure
times for DIC images were 100 ms. Scale bars, 5 mm. (B) Quantification of platelet surface area from WT and VAMP-32/2 Fg-spread platelets for indicated times. Data are
representative of 2 independent experiments (mean 6 SEM). (C) Quantification of static adhesion on 50 mg/mL human Fg and 5% bovine serum albumin-coated surfaces for
WT and VAMP-32/2 calcein-labeled platelets harvested from 3 different VAMP-32/2 and WT mice. Adherent platelets were measured by fluorescence, using a SpectraMax
plate reader. Data were plotted using SigmaPlot software (v13.0). (D) Representative images of thrombin-stimulated (0.05 U/mL; denoted by 1) clot retraction in WT and
VAMP-32/2 platelets at increasing times. (E) Clot sizes were measured, and the percentages of clot size relative to initial suspension volume (measured at time 0 and set as
100%) were determined and plotted. Three different VAMP-32/2 and corresponding WT littermate controls were used in this experiment. Statistical analyses were performed
using the Student t test; *P # .05; **P # .01; ***P # .001; n.s., not significant.

VAMP-32/2 platelets showed a slight enhancement in spreading on
ﬁbronectin (0.0728 mm2/min for VAMP-32/2 vs 0.0481 mm2/min for
WT) over time (P # .01 at 60 minutes and P # .05 at 120 minutes), but
not on poly-D-lysine- or on albumin-coated coverslips (supplemental
Figure 9). Consistent with increased spreading on ﬁbrinogen, clot
retraction was also faster in VAMP-32/2 platelets compared with WT
(Figure 6D-E). Unlike spreading, which is a linear function, clot

retraction proceeded exponentially over time, with the decay constant
for WT being 0.011% of initial clot size/min and that for VAMP-32/2
0.015% of initial clot size/min. This led to a 36% enhancement in the
rate of clot retraction in the VAMP-32/2 platelets as early as 30 minutes
(P # .05) and continued at 60 minutes (P # .05) and 120 minutes
(P # .05). Exogenous Fg was added in excess and was not limiting.
Thus, loss of VAMP-3 led to enhanced platelet spreading and clot
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retraction. However, these alterations did not affect platelet aggregation
or hemostasis, as measured by tail-bleeding assay (supplemental
Figure 10; Schraw et al32).

Discussion
Ours is the ﬁrst report that the v-SNARE, VAMP-3, is involved in
internal membrane trafﬁcking in platelets. This trafﬁcking is needed
for Fg and transferrin uptake/accumulation, platelet spreading, clot
retraction, and proper regulation of TPOR signaling. Loss of VAMP-3
did not affect platelet counts or ultrastructure (supplemental Table 1;
Schraw et al 32 ). Static levels of total surface and activated
aIIbb3 were unaltered in resting and thrombin-stimulated VAMP-32/2
platelets (supplemental Figure 2A-B), as was the steady-state binding of
Fg (supplemental Figure 2C). We previously reported32 that VAMP-3
played no signiﬁcant role in platelet exocytosis, and its loss did not
overtly affect tail-bleeding times (supplemental Figure 10). Thus,
the loss of VAMP-3 had no gross effects on the platelet’s role in
hemostasis, despite effects on platelet spreading and clot retraction.
Loss of VAMP-3 did affect Fg endocytosis, accumulation, and
trafﬁcking. We also characterized some of the routes taken by
endocytosed cargo and demonstrated that VAMP-3 plays a role in at
least 1 step. Given this phenotypic proﬁle, the VAMP-32/2 mice
described here will be valuable in determining if and how endocytosis
affects platelet biology.
In this manuscript, we describe a plate-based system that allows
more ﬂexibility and more sensitivity when assaying endocytosis than
ﬂow cytometry. Using this assay, we showed that Fg and transferrin
internalization reached saturation in WT platelets and demonstrated
classical receptor-ligand saturation kinetics over the range of concentrations tested (Figure 2C,E; supplemental Figures 3A,C and 6). Conversely, ﬂuid-phase pinocytosis of small molecules, that is, dextran,
was constitutive, rapid, and at least 1000-fold higher in capacity than
receptor-mediated Fg or transferrin uptake. This is some of the ﬁrst
evidence that platelets have at least 2 distinct mechanisms for taking up
molecules from their surrounding microenvironment. Despite these
differences in initial uptake, there is overlap in where the molecules go
inside the platelet. Over time, both types of cargo colocalized, ﬁrst with
Rab4 and then with Rab11. At the later times, the cargoes are found
colocalized with VWF, a marker for a-granules. These data conﬁrm
previous reports in which endocytosed Fg passes through Rab41
Early endosome, Rab111 Recycling endosomes, and multivesicular
bodies on the way to a-granules.28,39 VAMP-32/2 platelets had a
robust defect in Fg and transferrin uptake/accumulation (Figures 1
and 2; supplemental Figure 6). Given the distribution of endocytosed
Fg in the few Fg1, VAMP-32/2 platelets we could ﬁnd, this
v-SNARE could be involved at the step mediating entry into the
Rab41 compartment (Figure 4). Initial uptake of dextran was not
affected by VAMP-3’s loss (Figure 2D,F; supplemental Figure 5), but
transit of endocytosed dextran (Figures 4 and 5) and its accumulation at
longer times in vivo (24 hours) was defective (Figure 3B). These data
argue that VAMP-3 is required for at least 1 endocytic step that is
needed to accumulate both ﬂuid-phase-endocytosed and receptormediated-endocytosed material. This step is likely where the 2 routes
converge at a Rab41 compartment. Because entry to the Rab41
compartment is probably disrupted, it is difﬁcult to assess the role of
VAMP-3 in subsequent steps.
By affecting an early step in the trafﬁcking of speciﬁc surface
receptors (both liganded and empty), the loss of VAMP-3 could reroute
these receptors to and from the plasma membrane. Our previous studies
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showed that the small GTPase Arf6 was important for Fg uptake/
accumulation, integrin recycling, and some platelet functions; for
example, clot retraction and spreading.28 VAMP-32/2 platelets had a
similar phenotype, suggesting a similar role. In epithelial cells, VAMP-3
is important for integrin-mediated migration, particularly trafﬁcking
at the lamellipodia, where VAMP-3 localizes to focal adhesions.43
Tetanus toxin cleavage of VAMP-3 reduced migration, but enhanced
adhesion to collagen, laminin, and ﬁbronectin, perhaps because of impaired recycling of b1 integrins.43 In Figure 6A-B and supplemental
Figure 9, the rate of platelet spreading on immobilized Fg and Fn was
faster for VAMP-32/2 than WT platelets. This, together with the Arf62/2
phenotype, reinforces the notion that altered integrin trafﬁcking affects
platelet spreading. Unlike epithelial cells where migration is polarized,
platelet spreading on coated coverslips occurs in all directions. If
VAMP-3 controls spatially speciﬁc receptor trafﬁcking that facilitates
vectorial platelet spreading in a thrombus, its loss could make random,
multidirectional fusion more efﬁcient, leading to enhanced spreading
in all directions. Although we favor this explanation because it can
be applied to both VAMP-32/2 and Arf62/2 platelets,28 there is a valid
alternative. Loss of VAMP-3 could affect the formation of exocytic
SNARE complexes. VAMP-32/2 platelets have a modest secretion
rate enhancement.32 In contrast, loss of VAMP-7, another key platelet v-SNARE, causes a defect in a-granule secretion and platelet
spreading.45 Given that VAMP-7-mediated exocytosis is important
for spreading, VAMP-3-mediated enhanced secretion could enhance spreading. By reducing the levels of a potential competitive
v-SNARE,46 loss of VAMP-3 could increase the formation of other
SNARE complexes (containing VAMP-7 or VAMP-8, Syntaxin-8
or Syntaxin-11, and SNAP-23), and thus increase the exocytosis
events needed for spreading. Future comparisons of VAMP-32/2
and VAMP-72/2 platelets will be invaluable in understanding
how endo- and exocytosis affect platelet spreading. The enhanced
spreading and clot retraction phenotypes we observed are subtle and
might be expected to predispose the mice toward a more prothrombotic
phenotype. However, that was not obvious in the tail-bleeding or
FeCl3-injury models (Schraw et al32; supplemental Figure 10; S.J.
and S.W.W., manuscript in preparation). Equally, loss of VAMP-7
had no effect on tail-bleeding and laser-induced thrombosis45; thus, more
reﬁned assays will be needed to parse the biological ramiﬁcations of
the loss of these 2 v-SNAREs.
Platelets contain roughly 50 a-granules,47,48 yet we did not see
equivalent numbers of Fg1 puncta in platelets at 30 minutes or even
after the overnight incubation in vivo (Figures 2G-H, 3, 4, and 5). The
global distribution of Fg into a-granules, seen in recent immunoelectron microscopy studies, would seem at odds with our data.49 Although
clearly megakaryocytes endocytose Fg (supplemental Figure 4), it is
not clear whether all granules are loaded equally. At least for platelets,
our observations could mean that only speciﬁc a-granules are readily
loaded with endocytosed cargo during circulation. Alternatively, our
data could imply that Fg loading into all a-granules requires more
time, perhaps the lifetime of a platelet. It is equally possible that
larger amounts of FITC-Fg are needed to fully label all the granules.
Testing these possibilities will require future experiments, but will
yield a more detailed understanding of a-granule biogenesis and
the potential for creating heterogeneity in a-granule populations as
platelets circulate.
Endocytosis is a multistage process that uses several routes of
entry-transit-exit. Our data suggest that many of these paths are
present and active in platelets. Clearly, VAMP-3 and Arf6 mediate
some but not all the key steps that can facilitate Fg uptake/accumulation
and the dynamic processes that affect contact-based signaling; that
is, spreading and clot retraction. The VAMP-3-dependent and
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Arf6-dependent steps seem more important for receptor-mediated
endocytosis than ﬂuid-phase uptake. Platelets do have a robust ﬂuidphase pinocytosis system that likely takes in a host of small molecules.
Our data show that these cargoes are trafﬁcked to distinct compartments within the platelet. Thus, endocytosis may allow platelets to
actively sample their environment and perhaps interpret what they
sample. The VAMP-32/2 mice described here and the Arf62/2 mice
described previously28 offer unique reagents to begin to parse the
complexity of platelet endocytosis and to better deﬁne its physiological
relevance.
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